サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791760

眼科臨床試験の世界市場

Ophthalmic Clinical Trials

出版日
ページ情報
英文 162 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
眼科臨床試験の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 162 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

眼科臨床試験の世界市場は2030年までに27億米ドルに達する見込み

2024年に18億米ドルと推定される眼科臨床試験の世界市場は、分析期間2024-2030年にCAGR 6.3％で成長し、2030年には27億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである眼科臨床試験薬は、CAGR 7.1%を記録し、分析期間終了時には20億米ドルに達すると予測されます。眼科臨床試験機器セグメントの成長率は、分析期間中CAGR 4.2%と推定されます。

米国市場は4億8,380万米ドルと推定、中国はCAGR6.1％で成長予測

米国の眼科臨床試験市場は、2024年に4億8,380万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.1%として、2030年までに4億2,610万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.0％と5.3％と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の眼科臨床試験市場- 主要動向と促進要因まとめ

眼科が臨床研究の温床となっている理由とは？

眼科分野はパラダイムシフトを迎えており、眼に関連する疾患の世界の増加に対処することを目的とした臨床研究活動が急増しています。加齢黄斑変性症（AMD）、糖尿病性網膜症、緑内障、ドライアイ症候群などの疾患負担の増加により、眼科臨床試験はかつてないペースで拡大しています。世界の人口の高齢化はこの動向の主な要因であり、視覚に関連する障害の有病率は加齢とともに急増します。同時に、糖尿病や長時間のスクリーン使用といったライフスタイルに関連した危険因子が、治療上のイノベーションの必要性を高めています。眼科は、疾患の進行を直接視覚化し正確に測定できるという点でユニークであり、これにより正確な転帰評価が容易になるため、製薬企業やバイオテクノロジー企業にとって特に魅力的な分野となっています。研究を加速させているもう1つの要因は、遺伝子および分子レベルでの眼病態生理学の理解が進み、より的を絞った個別化治療が可能になっていることです。さらに、眼科領域の臨床試験は、他の治療領域の臨床試験と比較して、エンドポイントが明確に定義されており、診断ツールも標準化されているため、被験者の募集が早く、スケジュールも短いことが多いです。このため、次世代医薬品、遺伝子治療、徐放性インプラント、再生医療アプローチに投資する業界大手と機敏な新興企業が混在し、あらゆるフェーズで豊富な眼科臨床試験のパイプラインが形成されています。

試験デザインにおける革新は眼科研究をどのように形成しているか？

眼科領域では、技術の進歩や効率的で患者中心の手法に対するニーズの高まりによって、臨床試験デザインの伝統的なパラダイムが根本的に変わりつつあります。中間データに基づいてプロトコールを修正できる適応試験デザインは、その柔軟性と効率性から人気を集めています。同様に、分散型やハイブリッド型の臨床試験モデルは、特に専門的な眼科医療へのアクセスが制限されている地理的に分散した集団において、より広範な患者の参加を可能にしています。モバイル眼科画像、遠隔視力検査アプリ、ウェアラブル眼圧モニターなどのデジタルヘルスツールの統合により、臨床試験にリアルタイムのモニタリング機能が導入され、クリニック受診への依存度が低下し、データ収集の精度が向上しています。人工知能（AI）と機械学習アルゴリズムは、画像バイオマーカーを分析し、疾患の進行を予測するために導入されており、これにより患者の選択とエンドポイントの決定の両方が最適化されています。こうした技術統合は、臨床試験のワークフロー、薬事申請、患者モニタリングプロセスの自動化にも役立っており、時間とコストの負担を大幅に軽減しています。さらに、外部妥当性と規制上の妥当性を高めるために、試験デザインにおいてリアルワールドデータ（RWD）とリアルワールドエビデンス（RWE）を用いることが重視されるようになってきています。FDAやEMAのような規制当局が革新的な臨床試験モデルに対してオープンになってきているため、スポンサーは新しいアプローチを試す権限を感じており、眼科臨床試験全体でさらなる近代化を推進しています。

多様な治療分野の需要を牽引する利害関係者とは？

眼科臨床試験の需要は、幅広い利害関係者によって推進されており、それぞれが研究エコシステムの形成において明確でありながら補完的な役割を果たしています。製薬会社やバイオテクノロジー会社は最前線に立ち、一般的な眼疾患と稀な眼疾患の両方に対応する新規治療薬の開発に努力しています。症状の治療から疾患の改善や予防へと業界全体がますますシフトしており、抗VEGF薬、遺伝子治療、幹細胞を用いた治療など、最先端の治療法への扉が開かれつつあります。眼科を専門とするCRO（医薬品開発業務受託機関）も極めて重要なパートナーとして台頭しており、試験デザイン、患者募集、世界の規制基準の遵守に関する専門知識を提供しています。学術・研究機関は引き続き初期段階の探索研究およびトランスレーショナル・リサーチの拠点であり、多くの場合、臨床開発を加速させるために業界関係者とコンソーシアムを組んでいます。患者擁護団体や非営利団体は、治験の優先順位を形成する上で影響力を持ちつつあり、患者中心のアウトカムやアクセシビリティに関する懸念が治験実施計画書で確実に対処されるようになっています。また、ベンチャーキャピタルやプライベートエクイティ企業からの投資が増加していることも大きな推進力となっており、ベンチャーキャピタルやプライベートエクイティ企業は眼科の新興企業やプラットフォーム技術に積極的に資金を提供しています。ヘルスケア提供の面では、統合眼科医療ネットワークや眼科専門クリニックが治験実施において重要な役割を果たしており、十分に特性化された患者集団や質の高い診断インフラへのアクセスを提供しています。このような多面的な利害関係者の関与は、治験の展望を広げるだけでなく、イノベーションが臨床的に意義があり、商業的に実行可能であることを保証しています。

眼科臨床試験市場の成長を加速させている特定の動向とは？

眼科臨床試験市場の成長は、進化する治療ニーズ、技術力、業界慣行に関するいくつかの要因によって牽引されています。主な成長要因は、特殊な試験デザインと規制経路を必要とする単発性網膜疾患に合わせた精密医療と遺伝子治療プラットフォームの急速な開発です。糖尿病のような慢性的な全身疾患の罹患率の増加は、糖尿病黄斑浮腫と糖尿病網膜症に焦点を当てた臨床試験を促進しています。さらに、世界のデジタルスクリーン使用の急増は、ドライアイ症候群や近視の増加に寄与しており、新規治療法の広範な研究を促しています。光干渉断層計（OCT）、眼底自発蛍光、マイクロペリメトリーなどの技術の進歩は、エンドポイントの精度を高め、治療効果のより微妙な評価を可能にしています。臨床試験の世界化も重要な要因の一つで、スポンサーはアジア太平洋、ラテンアメリカ、東欧の新興市場をますますターゲットにするようになり、大規模な患者プールと迅速なリクルートサイクルを利用できるようになっています。規制当局は早期審査メカニズム、条件付き承認、希少疾病用医薬品の指定を通じて眼科臨床試験の承認を合理化しており、技術革新のインセンティブをさらに高めています。電子カルテとビッグデータ解析の利用拡大も、治験実施施設の選定、実現可能性評価、および患者の長期追跡調査を支援しています。最後に、生活の質（QoL）指標と患者報告アウトカムを重視する傾向が強まっているため、眼科臨床試験はより広範なヘルスケア価値の枠組みに沿ったものとなり、臨床と社会的期待の両方を満たすものとなっています。

セグメント

製品（眼科臨床試験薬、眼科臨床試験デバイス）;フェーズ（臨床フェーズ、探索フェーズ、前臨床フェーズ）;スポンサー（製薬/バイオ製薬企業、医療機器企業、その他スポンサー）

調査対象企業の例

  • Charles River Laboratories
  • CMIC Group
  • Covance Inc.
  • ICON plc
  • IQVIA
  • Iris Pharma
  • KCR
  • Labcorp Drug Development
  • Medpace
  • Novotech
  • Ora, Inc.
  • Parexel International
  • PPD（Pharmaceutical Product Development）
  • PRA Health Sciences
  • PRC Clinical
  • QuintilesIMS
  • Syneos Health
  • TFS HealthScience
  • Worldwide Clinical Trials
  • WuXi AppTec

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32424

Global Ophthalmic Clinical Trials Market to Reach US$2.7 Billion by 2030

The global market for Ophthalmic Clinical Trials estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Ophthalmic Clinical Trial Drugs, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Ophthalmic Clinical Trial Devices segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$483.8 Million While China is Forecast to Grow at 6.1% CAGR

The Ophthalmic Clinical Trials market in the U.S. is estimated at US$483.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$426.1 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.0% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Ophthalmic Clinical Trials Market - Key Trends & Drivers Summarized

What Makes Ophthalmology a Hotbed for Clinical Research Today?

The field of ophthalmology is undergoing a paradigm shift, with a surge in clinical research activity aimed at combating the global rise in eye-related disorders. Ophthalmic clinical trials are expanding at an unprecedented pace, driven by the increasing burden of diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and dry eye syndrome. The aging global population is a major contributor to this trend, as the prevalence of vision-related impairments escalates sharply with age. At the same time, lifestyle-related risk factors like diabetes and prolonged screen time are amplifying the need for therapeutic innovations. Ophthalmology is unique in that it allows for direct visualization and precise measurement of disease progression, which facilitates accurate outcome assessment-making it especially attractive for pharmaceutical and biotech companies. Another factor accelerating research is the evolving understanding of ocular pathophysiology at the genetic and molecular levels, enabling more targeted and individualized therapies. Furthermore, ophthalmic trials often involve faster recruitment and shorter timelines compared to trials in other therapeutic areas, due to well-defined endpoints and standardized diagnostic tools. This has attracted a mix of industry giants and nimble startups to invest in next-generation drugs, gene therapies, sustained-release implants, and regenerative medicine approaches, creating a rich pipeline of ophthalmic clinical trials across all phases.

How Are Innovations in Trial Design Reshaping Ophthalmic Research?

The traditional paradigms of clinical trial design are being radically transformed in the ophthalmology sector, spurred by technological advancements and the rising need for efficient, patient-centric methodologies. Adaptive trial designs, which allow for protocol modifications based on interim data, are gaining popularity for their flexibility and efficiency. Similarly, decentralized and hybrid clinical trial models are enabling broader patient participation, especially in geographically dispersed populations where access to specialized eye care is limited. The integration of digital health tools-such as mobile ophthalmic imaging, remote vision testing apps, and wearable intraocular pressure monitors-has brought real-time monitoring capabilities into clinical trials, reducing reliance on in-clinic visits and improving data collection accuracy. Artificial intelligence (AI) and machine learning algorithms are being deployed to analyze imaging biomarkers and predict disease progression, thereby optimizing both patient selection and endpoint determination. These technological integrations are also helping in the automation of trial workflows, regulatory submissions, and patient monitoring processes, significantly reducing time and cost burdens. Moreover, there is growing emphasis on using real-world data (RWD) and real-world evidence (RWE) in trial design to enhance external validity and regulatory relevance. As regulators such as the FDA and EMA show increasing openness to innovative trial models, sponsors are feeling more empowered to experiment with novel approaches, driving further modernization across ophthalmic clinical trials.

Which Stakeholders Are Driving Demand Across Diverse Therapeutic Fronts?

The demand for ophthalmic clinical trials is being propelled by a broad spectrum of stakeholders, each playing a distinct yet complementary role in shaping the research ecosystem. Pharmaceutical and biotechnology companies are at the forefront, striving to develop novel therapeutics that address both common and rare ocular diseases. Increasingly, there is an industry-wide shift from treating symptoms to disease modification and prevention, which has opened the door for cutting-edge therapies such as anti-VEGF agents, gene therapies, and stem cell-based interventions. Contract Research Organizations (CROs) specializing in ophthalmology have also emerged as pivotal partners, providing expertise in study design, patient recruitment, and compliance with global regulatory standards. Academic and research institutions continue to be hubs for early-stage discovery and translational research, often working in consortia with industry players to accelerate clinical development. Patient advocacy groups and nonprofit organizations are becoming influential in shaping trial priorities, ensuring that patient-centric outcomes and accessibility concerns are addressed in study protocols. Another significant driver is the rising investment from venture capital and private equity firms, which are actively funding ophthalmic startups and platform technologies. On the healthcare delivery front, integrated eye care networks and specialized ophthalmology clinics are playing a crucial role in trial execution, offering access to well-characterized patient populations and high-quality diagnostic infrastructure. The involvement of these multifaceted stakeholders is not only expanding the trial landscape but also ensuring that innovations are clinically meaningful and commercially viable.

What Specific Trends Are Accelerating Growth in the Ophthalmic Trials Market?

The growth in the ophthalmic clinical trials market is driven by several factors related to evolving therapeutic needs, technological capabilities, and industry practices. A key growth driver is the rapid development of precision medicine and gene therapy platforms tailored for monogenic retinal diseases, which require specialized trial designs and regulatory pathways. The rising incidence of chronic systemic diseases like diabetes is fueling trials focused on diabetic macular edema and diabetic retinopathy. Additionally, the global surge in digital screen usage is contributing to an increase in dry eye syndrome and myopia, prompting extensive research into novel treatment modalities. Technological advancements such as optical coherence tomography (OCT), fundus autofluorescence, and microperimetry are enhancing endpoint precision and enabling more nuanced evaluations of treatment efficacy. The globalization of clinical trials is another critical factor, with sponsors increasingly targeting emerging markets in Asia-Pacific, Latin America, and Eastern Europe to tap into large patient pools and faster recruitment cycles. Regulatory agencies are streamlining ophthalmic trial approvals through accelerated review mechanisms, conditional approvals, and orphan drug designations, further incentivizing innovation. The growing use of electronic health records and big data analytics is also supporting site selection, feasibility assessments, and long-term patient follow-up. Lastly, an increasing emphasis on quality of life (QoL) metrics and patient-reported outcomes is aligning ophthalmic trials with broader healthcare value frameworks, ensuring they meet both clinical and societal expectations.

SCOPE OF STUDY:

The report analyzes the Ophthalmic Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Ophthalmic Clinical Trial Drugs, Ophthalmic Clinical Trial Devices); Phase (Clinical Phase, Discovery Phase, Preclinical Phase); Sponsor (Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies, Other Sponsors)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Charles River Laboratories
  • CMIC Group
  • Covance Inc.
  • ICON plc
  • IQVIA
  • Iris Pharma
  • KCR
  • Labcorp Drug Development
  • Medpace
  • Novotech
  • Ora, Inc.
  • Parexel International
  • PPD (Pharmaceutical Product Development)
  • PRA Health Sciences
  • PRC Clinical
  • QuintilesIMS
  • Syneos Health
  • TFS HealthScience
  • Worldwide Clinical Trials
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Ophthalmic Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Vision Disorders Throws the Spotlight on Accelerated Ophthalmic Drug Development
    • Advances in Ocular Imaging Technologies Spur Growth in Precision-Driven Clinical Trial Endpoints
    • Patient-Centric Trial Models Expand Addressable Market Opportunity for Remote and Hybrid Ophthalmic Studies
    • Increased Focus on Rare and Genetic Eye Diseases Strengthens the Business Case for Specialized Trials
    • Biotech and Pharma Collaboration Accelerates Demand for Outsourced Ophthalmic Research Expertise
    • Digital Health Tools and Wearables Generate Opportunities for Real-Time Monitoring in Ophthalmic Trials
    • Artificial Intelligence in Image Analysis Enhances Efficiency and Accuracy of Clinical Outcome Assessments
    • Pediatric and Geriatric Trial Demographics Propel Growth in Age-Specific Study Designs and Delivery Models
    • Rising Investments in Gene Therapy and Regenerative Medicine Drive the Need for Complex Ophthalmic Trials
    • Globalization of Clinical Research Sites Sustains Growth by Broadening Access to Diverse Patient Populations
    • Risk-Based Monitoring and eSource Technologies Drive Adoption of Decentralized Clinical Trial Frameworks
    • Increased Emphasis on Quality-of-Life Metrics Generates Demand for Holistic Trial Outcomes Beyond Vision Acuity
    • Growing Involvement of Advocacy Groups and Patient Registries Strengthens Recruitment and Retention Strategies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ophthalmic Clinical Trials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Ophthalmic Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Ophthalmic Clinical Trial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trial Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Ophthalmic Clinical Trial Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Clinical Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Clinical Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Discovery Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Discovery Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Preclinical Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Preclinical Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical / Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pharmaceutical / Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Sponsors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • JAPAN
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • CHINA
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • EUROPE
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • FRANCE
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • GERMANY
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • UNITED KINGDOM
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030

IV. COMPETITION